Website profile

Cancernetwork

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

  • 158articles · 30d
  • 2+ day agolatest article
  • Aug 14, 2026earliest in window
  • 94%with images
  • 253avg words
articles per day
Categories
  • Health 158
  • Medical 157
  • Health & Wellness 153
  • Business & Industrial 3
  • Finance & Business 1
  • Jobs & Education 1
  • STEM 1

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

@onclive
cancernetwork.com > view > treatment-strategies-for-biomarker-negative-and-pi3k-pathway-altered-hr-her2-mbc

Treatment Strategies for Biomarker-Negative and PI3K-Pathway Altered HR+/HER2??? mBC

2+ day, 21+ hour ago   (207+ words) Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA Kamel Abou Hussein, MD; Kate Baxstrom, MD Geoffrey…...

@onclive
cancernetwork.com > view > eu-approves-t-dxd-pertuzumab-for-frontline-her2-metastatic-breast-cancer

EU Approves T-DXd/Pertuzumab for Frontline HER2+ Metastatic Breast Cancer

1+ week, 3+ day ago   (404+ words) The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency and…...